How soon will digital endpoints become a cornerstone for future drug development?
Boehme, Philip and Hansen, Arne and Roubenoff, Ronenn and Scheeren, Joseph and Herrmann, Maximilian and Mondritzki, Thomas and Ehlers, Jan and Truebel, Hubert (2018) How soon will digital endpoints become a cornerstone for future drug development? Drug Discovery Today. ISSN 18785832
Abstract
Digital technologies are transforming healthcare and will provide the basis for more patient-centric innovation in the pharmaceutical industry. Digital endpoints in clinical studies have the potential to drive innovation and reduce costly late-stage failures. This is also currently under consideration by regulatory agencies, such as the US Food and Drug Administration (FDA). The academic–industrial collaboration MOBILISED-D aims to implement and validate real-world walking speed (RWS) as a digital endpoint accepted by regulatory authorities as a first of its class. Previous work has shown that loss of mobility driven by chronic illness and frailty in older patients can be a relevant readout or effect of different diseases and various organ systems.
Item Type: | Article |
---|---|
Date Deposited: | 09 Oct 2018 00:45 |
Last Modified: | 09 Oct 2018 00:45 |
URI: | https://oak.novartis.com/id/eprint/37286 |